Research Purposes Only

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR. Research demonstrates up to 24.2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists. Phase 2 data shows 86% liver fat reduction in MASLD and -2.02% HbA1c reduction in type 2 diabetes.

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR. Research demonstrates up to 24.2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists. Phase 2 data shows 86% liver fat reduction in MASLD and -2.02% HbA1c reduction in type 2 diabetes.

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR. Research demonstrates up to 24.2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists. Phase 2 data shows 86% liver fat reduction in MASLD and -2.02% HbA1c reduction in type 2 diabetes.

• 29-amino acid synthetic polypeptide representing biologically active N-terminal fragment of human GHRH
• FDA-approved 1990 (diagnostic) and 1997 (therapeutic) for pediatric GH deficiency; stimulates physiological pulsatile GH release via GHRH-R Gs-cAMP-PKA signaling
• Extensively validated in clinical trials spanning growth disorders, aging research, cognitive function, and body composition management

Sermorelin (GHRH(1-29)-NH₂) is a 29-amino acid synthetic fragment of human growth hormone-releasing hormone with C-terminal amidation. FDA-approved (1991 diagnostic, 1997 therapeutic), it activates pituitary GHRH-R via Gs-cAMP-PKA signaling while preserving physiological pulsatile GH secretion and somatostatin feedback regulation.

• Synthetic mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates 5,000-fold at inner mitochondrial membrane through high-affinity cardiolipin binding
• FDA-approved September 2025 as Forzinity for Barth syndrome — first FDA-approved mitochondria-targeted therapeutic
• Extensively validated in 200+ peer-reviewed publications spanning cardiac, renal, neurological, and musculoskeletal research; multiple Phase 2/3 clinical trials completed